Singapore eDevelopment Ltd (SeD) is pleased to announce that its U.S. biomedical subsidiary Global BioLife Inc. has developed 3F Antimicrobial Fragrance, which shows efficacy against tuberculosis. Tuberculosis is the leading cause of deaths from a single infectious agent, infecting about one quarter of the world’s population.
The fragrance was shown to inhibit Mycobacterium tuberculosis (MTB), the causative bacterial agent of tuberculosis. The experiments were performed at ATCC, as a custom service within its High Containment Laboratory under BioSafety Level 3 conditions. ATCC is a premier global biological materials and information resource and standards organization, with proven expertise in the safe handling and experimentation on dangerous pathogens such as MTB.
Mr. Daryl Thompson, Global BioLife’s Director of Scientific Initiatives, and a Nobel Prize nominee in 2015 and 2016 for his research on pandemic technology, leads research on the 3F Antimicrobial Fragrance. “3F works by taking advantage and exploiting the bacterial or viral sophisticated communication system called quorum sensing.
“In essence, we can utilise quorum sensing to instruct the bacterial or viral agent to shut down or stop replication.The 3F project was designed to provide a solution for open environment defence strategies, to prevent or suppress the transmission of aerosoled viral and bacterial particles that cause the spread of influenza, MRSA and tuberculosis in congested areas. The process has been demonstrated to be very effective.”
As a leading developer of authenticated cells lines and microorganisms, ATCC was honored to provide Global BioLife with custom susceptibility testing to determine if their product was able to kill MTB–Dr. Manzour Hazbon, ATCC Senior Scientist
“This fragrance is very effective even in low concentrations, and an excellent candidate to treat tuberculosis, particularly important as there are few antibiotics effective in treating antibiotic-resistant tuberculosis cases.”
Mr Chan Heng Fai, Executive Chairman of SeD said, “We are excited about the potential of this breakthrough in 3F Antimicrobial, and Global GioLife will step up in its continued efforts to provide cutting edge research into real solutions for global healthcare problems.”
Dr. Roscoe M. Moore Jr, former Senior Assistant Surgeon General of the U.S. and highly-regarded public health expert who serves as Senior Scientific Adviser to Global BioLife, says “I’m excited about 3F’s potential to address a global epidemic by providing safe and versatile protection layers.”
“Tuberculosis is a global priority and Global BioLife’s solution will help save lives on a global scale.” Dr. Moore also served as Epidemic Intelligence Service Officer with the U.S. Center for Disease Control and Prevention, and as Chief Epidemiologist with the Center for Devices and Radiological Health in the U.S. Food and Drug Administration.
Also advising Global BioLife is Lieutenant Colonel William H. Lyerly Jr., a former Scientific Professional (ST) with the U.S. Government Civil Service and retired U.S. Army Medical Service Corps Officer with an extensive medical background including disaster relief, development, biodefense, interagency and civilmilitary cooperation and teaching.
“As TB’s person-to-person spread requires only a small number of bacteria and transmission is most rapid in confined spaces, 3F efficacy is especially promising. And as multidrug-resistant TB continues a global health crisis and security threat, 3F’s environmental intervention represents an effective and less-costly TB control strategy in high-transmission areas worldwide.”
Global Biolife has partnered with Destum Inc to license its 3F technology to global manufacturers and distributers. 3F Mosquito, unlike repellents such as DEET, was developed as an additive to laundry detergents and lotions for layered protection against mosquitos. 3F Antimicrobial was developed as an additive for sprays, filters and dispersal systems in hospitals, transit and open areas to protect against bacteria and viruses.
Global BioLife (GBLI) is 70%-held by Global BioMedical, owned by Singapore BioMedical Ltd, owned by Singapore eDevelopment. 20% held by Global Research & Discovery Group LLC (GRDGS) and 10% by ASX-listed Holista CollTech. Tapping GRDGS & Holista expertise, GBLI pledges a concerted effort at prevention and treatment of neurological, oncology and immuno-related diseases